1. CADTH Symposium: April 2015
In the past year…
• HC → market authorization for 2 infliximab SEBs
• Private plans → funding of SEBs
• CDR → SEB evaluation framework
• CDR → positive recommendation: Inflectra
• INESSS → recommendation for listing: Inflectra
• ‘prix le plus bas’ + ‘no sub’ policy changes
• PCPA → negotiations underway
• Pharma manufacturers pursuing SEB pipelines
• CADTH rapid response on SEB switcing
2. CADTH Symposium: April 2015
Panelist Objectives
• In the past year…
• what questions have been answered?
• what questions remain?
• what new questions have arisen?
• Panelists
• Cheryl Koehn, Arthritis Consumer Experts
• Brian Feagan, Robarts Clinical Trials, Western University
• Carlyn Volume-Davis, Alberta Blue Cross
• Judy McPhee, Nova Scotia Dept of Health & Wellness
• Chander Seghal, Common Drug Review